Alain Baron is president and CEO of two start-ups: the better-than-metformin metformin company Elcelyx Therapeutics Inc., and NaZura BioHealth Inc., which is developing a nutritional supplement for weight loss. The two efforts share an entire management team and investor base, and were split into two entities to better facilitate an exit for the companies’ investors. The firms do not, however, share a “For Sale” sign.
That is exclusively for Elcelyx. Baron said during an interview at J.P. Morgan Monday that the company is in talks with several large players in the diabetes space. Newmet, a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?